JILLIAN LISIAKOWSKI: Open Payments
NPI 1609475151 · ORANGE CITY, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,076 in 85 payments from 32 companies in 2025. Trend: 2023 $14 · 2024 $0 · 2025 $2,076
Food & beverage: $1,898Education: $178
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 10 | $223 |
| AstraZeneca Pharmaceuticals LP | 8 | $218 |
| Novartis Pharmaceuticals Corporation | 7 | $155 |
| E.R. Squibb & Sons, L.L.C. | 2 | $155 |
| Incyte Corporation | 5 | $155 |
| Eisai Inc. | 6 | $136 |
| Janssen Biotech, Inc. | 6 | $120 |
| Ipsen Biopharmaceuticals, Inc | 1 | $100 |
| Alexion Pharmaceuticals, Inc. | 4 | $93 |
| Geron Corporation | 4 | $68 |
Products named: KEYTRUDA, REBLOZYL, Lenvima, KISQALI, ULTOMIRIS, IMFINZI, RYBREVANT, CALQUENCE.
Industry payments across FL — which companies pay providers there.
